Vasculopathy
6
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Cardiac Allograft Vasculopathy Inhibition With Alirocumab
Evaluation of Accelerated Sampling Techniques for Vessel Wall Imaging
Statin InTensity to Prevent Coronary Artery Vasculopathy After Heart Transplantation
The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients
Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome
Cardiac Allograft Vasculopathy and Dobutamine Stress Echocardiography / Brain Natriuretic Peptide Coupling